Cargando…
SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer
SIMPLE SUMMARY: Overexpression of BQ can confer tamoxifen resistance in ER +ve breast cancer. BQ is a variant of NCOR2 spliced through the exclusion of exon 11. SRSF5 is found to be involved in regulating the splicing of NCOR2. A low expression of SRSF5 enhances the chance of excluding exon 11 from...
Autores principales: | Tsoi, Ho, Fung, Nicholas Nok-Ching, Man, Ellen P. S., Leung, Man-Hong, You, Chan-Ping, Chan, Wing-Lok, Chan, Sum-Yin, Khoo, Ui-Soon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136643/ https://www.ncbi.nlm.nih.gov/pubmed/37190199 http://dx.doi.org/10.3390/cancers15082271 |
Ejemplares similares
-
Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022) -
KPNA1 regulates nuclear import of NCOR2 splice variant BQ323636.1 to confer tamoxifen resistance in breast cancer
por: Tsoi, Ho, et al.
Publicado: (2021) -
A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2
por: Leung, Man-Hong, et al.
Publicado: (2020) -
Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022) -
Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)